Chemistry:Opnurasib
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C29H28ClN7O |
| Molar mass | 526.04 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Opnurasib (JDQ-443) is a small-molecule covalent KRASG12C inhibitor developed for non-small-cell lung cancer.[1][2][3][4]
References
- ↑ Weiss, Andreas; Lorthiois, Edwige; Barys, Louise; Beyer, Kim S.; Bomio-Confaglia, Claudio; Burks, Heather; Chen, Xueying; Cui, Xiaoming et al. (2 June 2022). "Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C". Cancer Discovery 12 (6): 1500–1517. doi:10.1158/2159-8290.CD-22-0158. PMID 35404998.
- ↑ Lorthiois, Edwige; Gerspacher, Marc; Beyer, Kim S.; Vaupel, Andrea; Leblanc, Catherine; Stringer, Rowan; Weiss, Andreas; Wilcken, Rainer et al. (22 December 2022). "JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS G12C for the Treatment of Solid Tumors". Journal of Medicinal Chemistry 65 (24): 16173–16203. doi:10.1021/acs.jmedchem.2c01438. PMID 36399068.
- ↑ Lindsay, Colin R; Veluswamy, Rajwanth; Castro, Gilberto; Tan, Daniel Shao-Weng; Caparica, Rafael; Glaser, Sabine; Malhotra, Shweta; Boran, Aislyn et al. (1 June 2023). "A phase II trial of JDQ443 in KRAS G12C -mutated NSCLC with PD-L1 expression". Journal of Clinical Oncology 41 (16_suppl): TPS9158. doi:10.1200/JCO.2023.41.16_suppl.TPS9158.
- ↑ Cassier, Philippe Alexandre; Dooms, Christophe Alfons; Gazzah, Anas; Felip, Enriqueta; Steeghs, Neeltje; Rohrberg, Kristoffer Staal; De Braud, Filippo G.; Solomon, Benjamin J. et al. (1 June 2023). "KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C -mutated solid tumors including non-small cell lung cancer (NSCLC).". Journal of Clinical Oncology 41 (16_suppl): 9007. doi:10.1200/JCO.2023.41.16_suppl.9007.
 |  |
